Korean Circ J.  2023 Dec;53(12):840-842. 10.4070/kcj.2023.0287.

Type 2 Myocardial Infarction: Another Hidden Cause of Mortality During the COVID-19 Pandemic

• Cho EJ
• Byeon K
• Jeong YH

• KMID: 2548791
• DOI: http://doi.org/10.4070/kcj.2023.0287

Reference

1. Alsaidan AA, Al-Kuraishy HM, Al-Gareeb AI, et al. The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread. Immun Inflamm Dis. 2023; 11:e798. PMID: 36988260.

2. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021; 76:970–979. PMID: 33622981.

3. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022; 28:1461–1467. PMID: 35614233.

4. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019; 40:237–269. PMID: 30165617.

5. Glance LG, Joynt Maddox KE, Shang J, et al. The COVID-19 pandemic and associated inequities in acute myocardial infarction treatment and outcomes. JAMA Netw Open. 2023; 6:e2330327. PMID: 37624599.

6. Thyagaturu H, Roma N, Angirekula A, et al. Trends and outcomes of type 2 myocardial infarction during the COVID-19 pandemic in the United States. Korean Circ J. 2023; 53:829–839. PMID: 37880873.

7. Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021; 121:422–432. PMID: 33171520.

8. Chaudhary R, Bliden KP, Kreutz RP, et al. Race-related disparities in COVID-19 thrombotic outcomes: beyond social and economic explanations. EClinicalMedicine. 2020; 29:100647. PMID: 33251501.

9. Hayashi H, Izumiya Y, Fukuda D, et al. Real-world management of pharmacological thromboprophylactic strategies for COVID-19 patients in Japan: from the CLOT-COVID study. JACC Asia. 2022; 2:897–907. PMID: 36536621.

10. Kim HK, Tantry US, Park HW, et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J. 2021; 51:202–221. PMID: 33655720.